A daganatos érhálózat mint terápiás célpont nem kissejtes tüdorákban

Translated title of the contribution: Tumor vasculature as a therapeutic target in non-small cell lung cancer

B. Döme, Melinda Magyar

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Despite developments in conventional (chemo)radiotherapy and surgery, survival of non-small cell lung cancer (NSCLC) patients remains poor. Treatments with targeted molecular drugs offer novel therapeutic strategies. Bevacizumab, a recombinant anti-vascular endothelial growth factor (VEGF) antibody, is the antiangiogenic drug at the most advanced stage of development in the therapy of NSCLC. However, a number of questions and future challenges relating to the use of bevacizumab in NSCLC remain. Furthermore, novel agents targeting the pre-existing NSCLC vasculature (i.e. vascular disrupting agents, VDAs) or multiple tyrosine kinase inhibitors have emerged as unique drug classes delivering promising results in several preclinical and clinical studies. Herein, we review the most recent data using these novel targeted agents either alone or in combination with chemotherapy in NSCLC.

Original languageHungarian
Pages (from-to)247-259
Number of pages13
JournalMagyar Onkologia
Volume52
Issue number3
DOIs
Publication statusPublished - 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasms
Pharmaceutical Preparations
Therapeutics
Combination Drug Therapy
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Blood Vessels
Radiotherapy
Survival
Antibodies
Bevacizumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A daganatos érhálózat mint terápiás célpont nem kissejtes tüdorákban. / Döme, B.; Magyar, Melinda.

In: Magyar Onkologia, Vol. 52, No. 3, 2008, p. 247-259.

Research output: Contribution to journalArticle

@article{2d5b4fa629df4b0a89d5d4e0a802fe66,
title = "A daganatos {\'e}rh{\'a}l{\'o}zat mint ter{\'a}pi{\'a}s c{\'e}lpont nem kissejtes t{\"u}dor{\'a}kban",
abstract = "Despite developments in conventional (chemo)radiotherapy and surgery, survival of non-small cell lung cancer (NSCLC) patients remains poor. Treatments with targeted molecular drugs offer novel therapeutic strategies. Bevacizumab, a recombinant anti-vascular endothelial growth factor (VEGF) antibody, is the antiangiogenic drug at the most advanced stage of development in the therapy of NSCLC. However, a number of questions and future challenges relating to the use of bevacizumab in NSCLC remain. Furthermore, novel agents targeting the pre-existing NSCLC vasculature (i.e. vascular disrupting agents, VDAs) or multiple tyrosine kinase inhibitors have emerged as unique drug classes delivering promising results in several preclinical and clinical studies. Herein, we review the most recent data using these novel targeted agents either alone or in combination with chemotherapy in NSCLC.",
keywords = "Angiogenesis, Lung cancer",
author = "B. D{\"o}me and Melinda Magyar",
year = "2008",
doi = "10.1556/MOnkol.52.2008.3.2",
language = "Hungarian",
volume = "52",
pages = "247--259",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - A daganatos érhálózat mint terápiás célpont nem kissejtes tüdorákban

AU - Döme, B.

AU - Magyar, Melinda

PY - 2008

Y1 - 2008

N2 - Despite developments in conventional (chemo)radiotherapy and surgery, survival of non-small cell lung cancer (NSCLC) patients remains poor. Treatments with targeted molecular drugs offer novel therapeutic strategies. Bevacizumab, a recombinant anti-vascular endothelial growth factor (VEGF) antibody, is the antiangiogenic drug at the most advanced stage of development in the therapy of NSCLC. However, a number of questions and future challenges relating to the use of bevacizumab in NSCLC remain. Furthermore, novel agents targeting the pre-existing NSCLC vasculature (i.e. vascular disrupting agents, VDAs) or multiple tyrosine kinase inhibitors have emerged as unique drug classes delivering promising results in several preclinical and clinical studies. Herein, we review the most recent data using these novel targeted agents either alone or in combination with chemotherapy in NSCLC.

AB - Despite developments in conventional (chemo)radiotherapy and surgery, survival of non-small cell lung cancer (NSCLC) patients remains poor. Treatments with targeted molecular drugs offer novel therapeutic strategies. Bevacizumab, a recombinant anti-vascular endothelial growth factor (VEGF) antibody, is the antiangiogenic drug at the most advanced stage of development in the therapy of NSCLC. However, a number of questions and future challenges relating to the use of bevacizumab in NSCLC remain. Furthermore, novel agents targeting the pre-existing NSCLC vasculature (i.e. vascular disrupting agents, VDAs) or multiple tyrosine kinase inhibitors have emerged as unique drug classes delivering promising results in several preclinical and clinical studies. Herein, we review the most recent data using these novel targeted agents either alone or in combination with chemotherapy in NSCLC.

KW - Angiogenesis

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=58149235293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149235293&partnerID=8YFLogxK

U2 - 10.1556/MOnkol.52.2008.3.2

DO - 10.1556/MOnkol.52.2008.3.2

M3 - Article

C2 - 18845495

AN - SCOPUS:58149235293

VL - 52

SP - 247

EP - 259

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 3

ER -